Effect on glycemic control by short- and long-term use of continuous glucose monitoring in clinical practice

Journal of Diabetes Science and Technology

Volumn 5, Issue 6, 2011, Pages 1472-1479

  Anderson, Jenny ^a   Attvall, Stig ^b,c   Sternemalm, Lennart ^c   Pivodic, Aldina ^d   Fahlén, Martin ^e   Hanås, Ragnar ^f   Ekeroth, Gunnar ^d   Lind, Marcus ^a,b  

^a Department of Oral and Maxillofacial Surgery Otolaryngology   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d Statistiska Konsultgruppen   (Sweden)

^e Kungälv Hospital   (Sweden)

^f NU Hospital Organization   (Sweden)

Author keywords

Continuous glucose monitoring; Hemoglobin A1c; Hypoglycemia; Indication; Long; Short

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADULT; ARTICLE; BLOOD; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; METHODOLOGY; MONITORING; SWEDEN;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MONITORING, PHYSIOLOGIC; SWEDEN;

EID: 84862701918     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500622     Document Type: Article

References (19)

1. Diabetes Control and Complications Trial Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
3. Jefcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med. 2004;21(7):657-65.
4. Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;(1):CD005103.
5. Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol. 2010;47(Suppl 1):77-81.
6. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjörnsdóttir S, Eliasson B. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care. 2010;33(7):1640-6.
7. Hirsch IB. Clinical review: realistic expectations and practical use of continuous glucose monitoring for the endocrinologist. J Clin Endocrinol Metab. 2009;94(7):2232-8.
8. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-20.
9. Dental and Pharmaceutical Benefits Agency. [Decision on reimbursement for glucose]. [Document in Swedish]. Stockholm: Dental and Pharmaceutical Benefits Agency; 2010. 2485/2010. Available from: http://www.tlv.se/Upload/Beslut-2010/ bes101222-minilink.pdf.
10. Lind M, Odén A, Fahlén M, Eliasson B. The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables. PLoS One. 2009;4(2):e4412.
11. Fahlén M, Eliasson B, Odén A. Optimization of basal insulin delivery in type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. Diabet Med. 2005;22(4):382-6. (Pubitemid 40516234)
12. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R, Mosca A, Mauri P, Paroni R, Susanto F, Takei I, Thienpont L, Umemoto M, Wiedmeyer HM; IFCC Working Group on HbA1c Standardization. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem. 2004;50(1):166-74. (Pubitemid 38125714)
13. Lind M, Fahlén M, Happich M, Odén A, Eliasson B. The effect of insulin lispro on glycemic control in a large patient cohort. Diabetes Technol Ther. 2009;11(1):51-6.
14. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009;180(4):385-97.
15. Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, Pieber TR. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med. 2005;165(12):1337-44. (Pubitemid 40973416)
16. Diabetes Control and Complications Trial Study Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44(8):968-83.
17. Lind M, Odén A, Fahlén M, Eliasson B. The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to timedependent effects. Diabetologia. 2010;53(6):1093-8.
18. Leinung M, Thompson S, Nardacci E. Benefits of continuous glucose monitor use in clinical practice. Endocr Pract. 2010;16(3):371-5.
19. Lind M. Glycaemic control: evaluation of HBA1c as a risk factor and the effect of modern insulins in clinical practice. Gothenburg (Sweden): Sahlgrenska Academy, University of Gothenburg; 2009. Available from: http://gupea.ub.gu.se/ handle/2077/19641.